Roivant Phase 2 PH-ILD trial cuts PVR 56%
Roivant reports strong Phase 2 mosliciguat data in PH-ILD and advances the program into a global Phase 3 trial targeting a large unmet-need population.
Rhea-AI Filing Summary
Roivant Sciences Ltd. (ROIV) reported positive topline results from its Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and has initiated the Phase 3 PHrontier trial. PH-ILD is described as a progressive, life‑threatening condition with significant unmet medical need.
PHocus met its primary endpoint with a placebo‑adjusted pulmonary vascular resistance (PVR) reduction of 56.3% at Week 16 (‑51.3% mosliciguat vs. +6.6% placebo; p<0.0001). Key secondary endpoints also favored mosliciguat, including a placebo‑adjusted improvement in six‑minute walk distance of 35.2 meters at Week 16 (p=0.0027) and a placebo‑adjusted NT‑proBNP reduction of 357.7 pg/mL, corresponding to a 53.2% decline from baseline (p=0.0002). Exploratory Week 24 data showed further gains in walk distance (+52.7 meters) and NT‑proBNP (‑487.1 pg/mL; ‑75.9%).
Mosliciguat was observed to be well tolerated with adverse events consistent with PH‑ILD; cough incidence was 12.1% on mosliciguat versus 18.2% on placebo. The global Phase 2 study enrolled 135 patients across 87 sites in 20 countries, and the Phase 3 PHrontier trial is planned to enroll approximately 375 patients with PH‑ILD.
Positive
- Phase 2 PHocus met primary and secondary endpoints, with a 56.3% placebo‑adjusted PVR reduction, clinically meaningful gains in six‑minute walk distance, and large NT‑proBNP reductions, supporting mosliciguat’s potential efficacy in PH‑ILD.
- Program advanced into Phase 3 PHrontier, a randomized global trial targeting approximately 375 PH‑ILD patients, signaling continued investment and a clear late‑stage development path.
- Favorable tolerability profile reported, with overall adverse events consistent with PH‑ILD and a lower cough incidence on mosliciguat (12.1%) than placebo (18.2%), notable versus other inhaled therapies.
- Large target population cited, with up to 200,000 PH‑ILD patients across the U.S. and Europe and limited or no approved treatment options, highlighting potential commercial opportunity if mosliciguat is ultimately approved.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Pulmonary vascular resistance reduction (primary endpoint): 56.3% placebo-adjusted reduction
Six-minute walk distance improvement (Week 16): 35.2 meters placebo-adjusted gain
NT-proBNP absolute change at Week 16: 357.7 pg/mL reduction
+5 more
8 metrics
Pulmonary vascular resistance reduction (primary endpoint)
56.3% placebo-adjusted reduction
Week 16 in Phase 2 PHocus trial; -51.3% mosliciguat vs. +6.6% placebo (p<0.0001)
Six-minute walk distance improvement (Week 16)
35.2 meters placebo-adjusted gain
Phase 2 PHocus secondary endpoint; +20.3 meters mosliciguat vs. -14.9 meters placebo (p=0.0027)
NT-proBNP absolute change at Week 16
357.7 pg/mL reduction
Placebo-adjusted reduction corresponding to a 53.2% decline from baseline (p=0.0002)
Exploratory six-minute walk distance improvement (Week 24)
52.7 meters placebo-adjusted gain
Pre-specified exploratory analysis at end of placebo-controlled period (nominal p<0.0001)
Exploratory NT-proBNP reduction (Week 24)
487.1 pg/mL reduction (75.9%)
Placebo-adjusted reduction in NT-proBNP at Week 24 (nominal p<0.0001)
Cough incidence
12.1% mosliciguat vs. 18.2% placebo
Adverse event comparison in Phase 2 PHocus trial
PHocus enrollment
135 patients
Randomized across 87 sites in 20 countries
PHrontier planned enrollment
Approximately 375 patients
Phase 3 global PHrontier trial in PH-ILD
Key Terms
pulmonary vascular resistance, six-minute walk distance, NT-proBNP, sGC activator, +2 more
6 terms
pulmonary vascular resistance medical
"The PHocus study met its primary endpoint, demonstrating a ... reduction in PVR"
Pulmonary vascular resistance is the opposition blood faces as it flows through the small arteries and vessels in the lungs — think of it like the narrowness or roughness inside a garden hose that makes water harder to push through. Investors care because higher resistance indicates strain on the heart and worse outcomes for patients, so drugs, devices or tests that reliably lower it can drive clinical approvals, reduce hospital stays and create meaningful commercial value.
six-minute walk distance medical
"improvement in 6MWD of +35.2 meters ... at Week 16"
Six-minute walk distance (6MWD) is a simple test that measures how far a person can walk on a flat surface in six minutes, used to gauge overall heart and lung function and physical endurance. Investors care because changes in this distance in clinical studies can show whether a treatment meaningfully improves patients’ daily abilities, which influences regulatory approval, clinical value, market demand, and potential reimbursement — similar to measuring how much farther a car can drive after an upgrade.
NT-proBNP medical
"statistically significant reduction in NT-proBNP, a biomarker of cardiac strain"
A blood test marker released when the heart is under strain; higher NT‑proBNP levels indicate the heart is working harder or may be failing, similar to a dashboard warning light that signals engine stress. Investors watch NT‑proBNP because changes in the marker can drive clinical trial results, treatment approvals, hospital use, and insurance decisions for heart drugs and devices, all of which affect revenue, adoption and valuation in healthcare companies.
sGC activator medical
"Mosliciguat is a potential first-in-class, once-daily, inhaled sGC activator"
Group 3 PH medical
"PH is classified into five groups ... Group 3 PH is a subtype"
pulmonary hypertension associated with interstitial lung disease medical
"evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease"
High blood pressure in the vessels of the lungs that develops because the lung tissue has become scarred or inflamed; think of the heart trying to push blood through lungs whose tiny pipes have narrowed or stiffened. It matters to investors because this combined condition creates a clear medical need that can drive demand for new drugs, devices and tests, influence the outcome of clinical trials and regulatory decisions, and affect costs and revenues across healthcare companies.
FAQ
What did Roivant (ROIV) announce about the PHocus Phase 2 study of mosliciguat?
Roivant announced that Phase 2 PHocus met its primary endpoint with a 56.3% placebo‑adjusted PVR reduction at Week 16 and achieved key secondary endpoints, including improved six‑minute walk distance and reduced NT‑proBNP, in patients with PH‑ILD.
How effective was mosliciguat on pulmonary vascular resistance in Roivant’s PHocus trial?
Mosliciguat achieved a placebo‑adjusted pulmonary vascular resistance reduction of 56.3% at Week 16 (‑51.3% mosliciguat vs. +6.6% placebo, p<0.0001), which external clinical experts quoted in the release characterized as among the largest reported in randomized PH trials.
What functional and biomarker improvements were seen with mosliciguat in PH-ILD?
At Week 16, mosliciguat improved six‑minute walk distance by a placebo‑adjusted 35.2 meters (p=0.0027) and reduced NT‑proBNP by 357.7 pg/mL, a 53.2% decline from baseline (p=0.0002). Exploratory Week 24 data showed a 52.7‑meter walk improvement and 487.1 pg/mL NT‑proBNP reduction.
What safety and tolerability profile did mosliciguat show in Roivant’s Phase 2 PHocus study?
Mosliciguat was reported as well tolerated with a favorable safety profile and adverse events consistent with PH‑ILD. Notably, cough incidence was 12.1% on mosliciguat versus 18.2% on placebo, important given cough concerns with some inhaled therapies.
What are the key design details of the Phase 3 PHrontier study for mosliciguat?
The Phase 3 PHrontier study is a randomized (1:1), double‑blind, placebo‑controlled, global trial evaluating mosliciguat in adult PH‑ILD patients. It is currently designed to enroll approximately 375 patients worldwide.
How large is the potential PH-ILD patient population Roivant is targeting with mosliciguat?
The company cites that up to 200,000 patients across the U.S. and Europe are living with PH‑ILD, a subset of Group 3 pulmonary hypertension, and currently have limited or no approved treatment options.
AI-generated analysis. How Rhea-AI works. Not financial advice.
